Lates News

Analysts said the failure of AstraZeneca's breast cancer drug trial could reduce the drug's potential sales by billions of dollars. The drug, called Etcamah, failed to delay disease progression more effectively than standard treatment in a late-stage study of breast cancer patients whose disease had recurred or spread but who had not yet received any treatment, the pharmaceutical company said late Friday. The failure could reduce peak sales by as much as $3.8 billion. AstraZeneca is known for developing blockbuster cancer drugs, and CEO Pascal Soriot now faces pressure to prove that the company's internal new drug pipeline can succeed. AstraZeneca also reported positive data over the weekend for two lung cancer drugs.